Shandong Chenxin Fodu Pharmaceutical Co., Ltd.

Primary objective: To evaluate the effectiveness of lifalast eye drops in the treatment of patients with dry eye. Secondary objective: To evaluate the safety of lifalast eye drops.

Main research objectives: Through fasting/postprandial test studies, the in vivo pharmacokinetic characteristics of the test preparation ibuprofen suspension (specification: 100 mL: 2 g, developed by Shandong Chenxin Fodu Pharmaceutical Co., Ltd.) and the reference preparation ibuprofen suspension (trade name: Meilin, specification: 100 mL: 2 g, produced by Shanghai Johnson Pharmaceutical Co., Ltd.) were investigated in healthy Chinese subjects after a single oral administration under fasting/postprandial conditions, and the bioequivalence of the two preparations was evaluated. Secondary research objectives: To evaluate the safety of a single oral administration of ibuprofen suspension 100 mL: 2 g test preparation and reference preparation in healthy Chinese subjects.

Main purpose of study: According to the relevant provisions of bioequivalence test, Anacor Pharmaceuticals, Inc. was selected as the reference preparation for the fasting topical administration of the test preparation crisaborole ointment (specification: 2%) produced by Shandong Chenxin Fodu Pharmaceutical Co., Ltd. to conduct a human bioequivalence test for topical administration of the test preparation crisaborole ointment (specification: 2%), to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under the condition of fasting topical administration. Secondary purpose of study: To observe the safety of the test preparation crisaborole ointment (specification: 2%) and the reference preparation crisaborole ointment (trade name: 2%) on an empty stomach in healthy volunteers.